Meeting Banner
Abstract #2196

Large Scale Comparison of Gadobenate Dimeglumine and Comparator Agents

Matthew J. Kuhn1, Howard A. Rowley2, Michael V. Knopp3, Kenneth R. Maravilla4, Zoran Rumboldt5

1Radiology, University of Illinois at Peoria, Peoria, IL, United States; 2Radiology, University of Wisconsin, Madison, WI, United States; 3Radiology, Ohio State University, Columbus, OH, United States; 4Radiology and Surgery, University of Washington, Seattle, WA, United States; 5Radiology, Medical University of South Carolina, Charleston, SC, United States

382 patients were randomized to receive 2 MR exams within 2 days to 2 weeks with equal 0.1mmo/kg doses of either gadobenate dimeglumine (N=382) or a comparator gadolinium agent. Blinded experts assessed post-contrast images for both qualitative (eg, global contrast enhancement, lesion-to-brain contrast, lesion delineation, internal lesion morphology and structure, tumor vascularization, and global image preference) and quantitative (eg, contrast-to-noise ratio [CNR]; percent lesion enhancement) efficacy parameters. In all six studies, images produced following administration of Gd-BOPTA demonstrated greater contrast enhancement, provided more diagnostic information including additional lesion detection, and were significantly preferred by experienced, blinded neuroradiologists.